GlassScriptPhysician profile
George G Le-Bert
NPI 1033318928
$15,758.48
in general payments reported to CMS, 2019-2025
38 companies · $3,524 in 2025
The $3,524 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,592 · 2020: $1,176 · 2021: $1,805 · 2022: $2,033 · 2023: $2,257 · 2024: $3,370 · 2025: $3,524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,981 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,980.98 |
| Education | $171.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,440.24 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,150.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,140.91 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $982.97 | 2019-2025 | Lifevest |
| Pfizer INC. | $901.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $877.70 | 2020-2025 | Farxiga, Wainua, Lokelma |
| Merck Sharp & Dohme LLC | $805.77 | 2021-2025 | Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $801.80 | 2021-2025 | |
| Amgen INC. | $765.40 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $673.66 | 2019-2024 | |
| Alnylam Pharmaceuticals INC. | $663.61 | 2023-2025 | Amvuttra, Onpattro |
| Novo Nordisk INC | $627.37 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Cvrx, INC. | $604.65 | 2021-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $591.53 | 2019-2025 | Camzyos, Eliquis, Coumadin |
| Abbott Laboratories | $512.57 | 2020-2025 | Mitraclip, Cardiomems |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $506.77 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $413.87 | 2019-2023 | |
| Irhythm Technologies, INC. | $341.61 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $231.75 | 2025 | |
| Bridgebio Pharma, INC. | $221.33 | 2025 | Attruby |
| United Therapeutics Corporation | $202.34 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $193.64 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Baxter Healthcare | $171.36 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Medtronic, INC. | $134.13 | 2021-2022 | |
| Abiomed | $123.65 | 2023-2025 | Impella |
| Lexicon Pharmaceuticals, INC. | $121.99 | 2023-2024 | Inpefa |
| Lundbeck LLC | $120.95 | 2019-2020 | |
| Boston Scientific Corporation | $76.01 | 2023-2024 | Watchman Flx, Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $59.33 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $50.48 | 2022-2023 | Arcalyst |
| Cordis US Corp. | $49.14 | 2025 | Mynx Control Venous |
| Kowa Pharmaceuticals America, INC. | $38.25 | 2019-2023 | Livalo |
| Philips North America LLC | $36.94 | 2025 | Extended Holter |
| Kestra Medical Technology Services, INC. | $31.26 | 2025 | Assure Wcd |
| Arbor Pharmaceuticals, INC. | $27.87 | 2019-2021 | |
| Medtronic Vascular, INC. | $25.44 | 2019-2020 | |
| Genzyme Corporation | $23.72 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Le-Bert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.